Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Monthly Archives: January 2015

MDMA Member Survey Shows Repealing Medical Device Tax Would Create Jobs, Increase R&D

Washington, DC, January 29, 2015 ― A new survey conducted by the Medical Device Manufacturers Association (MDMA) shows that if the medical device tax were repealed, the overwhelming majority of medical technology innovators would increase hiring and make new investments in research and development (R&D).

Conducted over November and December in 2014, the MDMA surveye consists of over 100 responses from medical technology executives.

Top findings of the survey include: Continue reading

AdvaMed Releases Member Survey of Medical Device Tax’s Negative Impact on Companies’ Jobs, R&D

Washington, DC, January 28, 2015 ― The Advanced Medical Technology Association (AdvaMed) today released the results of a new survey that details the negative and costly impact of the medical device tax, reflecting the tough choices companies are making to address it including reducing jobs, research and development (R&D) and other financial investments.

As a follow up to a survey completed in November 2013, AdvaMed conducted a survey of member companies at the end of 2014 to assess the ongoing effects of the medical device tax. The responses to the survey were generalized to the industry as a whole based on the ratio of revenues of responding companies to revenues of the overall industry. Continue reading

House Committee Unveils ’21st Century Cures’ Proposals; Rep. Pallone Expresses Concerns

Washington, DC, January 28, 2015 ― The U.S. House Energy and Commerce Committee on yesterday released an initial 393-page discussion document outlining some specific proposals that have been shared throughout the 21st Century Cures initiative.

According to the committee, this document seeks to continue the important dialogue of the past year, encouraging more discussion from patients, innovators, researchers, care givers, and other experts on the common goal of accelerating the pace of cures in the United States.

This product is the result of the invaluable input shared in response to the five white papers and at the eight hearings and numerous roundtables convened over the past year. Continue reading

Kaiser Family Foundation Poll: If Supreme Court Rules Against Obamacare Subsidies, Most Want Them Restored

Washington, DC, January 28, 2015 ― Kaiser Health News reports that a new poll finds that most people think Congress or states should act to restore health insurance subsidies if the U.S. Supreme Court decides later this year they are not permitted in states where the federal government is running the marketplace.

The court in March is set to hear King v. Burwell, a lawsuit arguing that the wording of the Affordable Care Act means that financial assistance with premiums is available only in the 13 states that created and are running their own online insurance exchanges.

If the court sides with those challenging Obamacare, millions of people in the 37 states that use the federal Healthcare.gov site would lose the help they have been getting.  A decision in the case is expected in late June. Continue reading

9.5 Million Consumers Are Signed Up for Obamacare Marketplace

Washington, DC, January 27, 2015 ― Nationwide, 9.5 million consumers selected or were automatically reenrolled in quality, affordable health insurance coverage from the Health Insurance Marketplace through the second month of 2015 Open Enrollment, according to a report released today by the U.S. Department of Health and Human Services.

Of those, more than 7.1 million were in states using the HealthCare.gov platform and 2.4 million were in the 14 states (including Washington, D.C.) using their own Marketplace platforms. Continue reading

Medical Device Industry Works Hard to Repeal Obamacare Tax

Washington, DC, January 27, 2015 The Washington Post reports that Tom Till eyes the morning’s e-mail to see who’s angling to hire his students.  A local employer, which had already hired 23 people in less than a year, says it needs three more to help make the artificial hips, knees and other devices manufactured in Warsaw, Indiana, the self-proclaimed “Orthopedic Capital of the World.”

“Everyone is going gangbusters,” said Till, who oversees an advanced manufacturing program at Ivy Tech Community College in this lake-dotted region two hours north of Indianapolis.

The Post reports that Till’s bullish view of the medical device industry — he says he can’t crank out graduates fast enough — contrasts sharply with what industry lobbyists are telling lawmakers in the nation’s capital. Continue reading

Pharmalot: Report Finds Prescription Medicine Prices Rose in 2014

New York, NY, January 27, 2015 ― Pharmalot reports that the prices of prescription medicines is a front-and-center issue as the cost to treat everything from some of the rarest diseases to the most common afflictions is causing increasing concern among payers, physicians and consumers.

But how much exactly did prices rise last year?

A new analysis indicates prices rose significantly across the board for all types of medicines.   Continue reading

NJ Civil Justice Institute to Host ‘FDA Preemption: The Battle for Supremacy’ February 10 in Newark

Trenton, NJ, January 27, 2015 ― A wide variety of products are subject to regulation at the federal level by the Food and Drug Administration (FDA).  But those products are also effectively subject, in varying degrees, to ad hoc regulation at the state level via litigation.  The conflict between these two competing regulatory regimes is a growing concern.

The New Jersey Civil Justice Institute (NJCJI) will host a panel discussion entitled “FDA Preemption: The Battle for Supremacy” that will explore this developing area of law.

The event, which is being sponsored by McCarter & English, will be held on February 10 from Noon to 2:30 p.m. at McCarter & English’s Newark office. Continue reading

NYT: President to Request Research Funding for Treatments Tailored to Patients’ DNA

Washington, DC, January 26, 2015 The New York Times’ Robert Pear reports that President Obama will seek hundreds of millions of dollars for a new initiative to develop medical treatments tailored to genetic and other characteristics of individual patients, administration officials say.

The proposal, mentioned briefly in his State of the Union address, will be described in greater detail in his budget in the coming weeks.  The effort is likely to receive support from members of both parties, lawmakers said.

In his address, President Obama called it “precision medicine,” but the terms “personalized medicine” and “individualized medicine” are also widely used to describe the evolving field in which, for example, a doctor prescribes a medication that targets a specific mutation in a patient’s genes. Continue reading

Sen. Elizabeth Warren Wants Big Drugmakers that Break Law to Fund NIH

New York, NY, January 23, 2015 ― Pharmalot reports that, seeking to replenish funding for new scientific research, U.S. Sen. Elizabeth Warren (D-MA) plans to introduce a bill next week that would require drug makers that break the law to send some of their profits to the U.S. National Institutes of Health (NIH).

Under the Senator’s plan, drug makers that reach settlements with the federal government for paying kickbacks to doctors, defrauding Medicare or Medicaid or illegally marketing medicines would have to pay 1% of their annual profits for each blockbuster medicine that can be traced to public sector research. Continue reading